表位
无乳链球菌
血清型
生物
链球菌
病毒学
接种疫苗
微生物学
免疫系统
病菌
抗原
B组
毒力
人口
抗体
免疫学
医学
细菌
基因
内科学
环境卫生
生物化学
遗传学
作者
Yumin Zhang,Song Liang,Shiyu Zhang,Shidan Zhang,Yong Yu,Huochun Yao,Yongjie Liu,Wei Zhang,Guangjin Liu
标识
DOI:10.1080/22221751.2022.2122585
摘要
Streptococcus agalactiae (Group B Streptococcus, GBS) is a multi-host pathogen, even causing life-threatening infections in newborns. Vaccination with GBS crossed serotypes vaccine is one of the best options for long-term infection control. Here we built a comprehensive in silico epitope-prediction workflow pipeline to design a multivalent multiepitope-based subunit vaccine containing 11 epitopes against Streptococcus agalactiae (MVSA). All epitopes in MVSA came from the proteins which were antigenic-confirmed, virulent-associated, surface-exposed and conserved in ten GBS serotypes. The in-silico analysis showed MVSA had potential to evoke strong immune responses and enable worldwide population coverage. To validate MVSA protection efficacy against GBS infection, immune protection experiments were performed in a mouse model. Importantly, MVSA induced a high titre of antibodies, significant proliferation of mice splenocytes and elicited strong protection against lethal-dose challenge with a survival rate of 100% in mice after three vaccinations. Meanwhile, the polyclonal antibody against MVSA did not only inhibit for growth of GBS from six crucial serotypes in vitro, but also protect 100% naive mice from GBS lethal challenge. These active and passive immunity assay results suggested that MVSA could therefore be an efficacious multi-epitope vaccine against GBS infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI